Oral Cancer Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report, by Treatment, Age Group and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

Global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Oral cancer includes cancers of the mouth and the back of the throat. Oral cancers develop on the tongue, the tissue lining the mouth and gums, under the tongue, at the Oral Cancer Treatment Market base of the tongue, and the area of the throat at the back of the mouth. Furthermore, oral cancer accounts for approximately 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year. In addition, oral cancer most often occurs in people over the age of 40 and affects more than twice as many men as women. Most oral cancers are related to tobacco use, alcohol use (or both), or infection by the human papilloma virus (HPV).

Increase in demand for targeted mode of therapies, surge in the R&D activities for the development of novel drugs and therapies, high unmet need of treatment and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of oral cancer treatment market. Further, growing prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also raising the growth of the market. On the other hand, increasing personal disposable income coupled with rising prevalence of papillomavirus infection is other indirect cause that is expected to create lucrative growth opportunities for the market.

However, lack of awareness about oral cancer in the backward and underdeveloped areas will hamper the market growth. 

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, COVID-19 has positively impacted the oral cancer treatment market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Severe COVID‐19 represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which leads to acute respiratory distress syndrome. Its appearances can be viewed as a combination of the two processes that is viral pneumonia and acute respiratory distress syndrome. SARS‐CoV‐2 represents an ongoing worldwide threat, as this virus family has the potential to mutate and infect non‐immune population. Furthermore, Owing to the well-known major risk factors, oral cancer is considered a preventable disease and moreover, due to easy accessibility, it can be detected in early stages. Yet, majority of oral cancer cases in the developing countries are diagnosed in advanced stages, resulting in increased morbidity and mortality of oral cancer. Generally, dentists play a pivotal role in the early detection of oral cancer through opportunistic screening when a patient presents in a dental practice for routine care and by rapid referral of suspicious lesions. In the time of COVID-19, nevertheless, the whole world being in lockdown, and dental clinics are closed. Therefore, opportunities for screening the oral cavity might be significantly disrupted, and consequently diagnosis of malignant and/or potentially malignant lesions might be delayed, a matter that inevitably leads to a missed diagnosis of oral cancer or, at best, diagnosis later on but at a late stage.

Oral Cancer Treatment Market Segmentation  

The global oral cancer treatment market is segmented into drug type, age group, distribution channel, and region. Depending on treatment, the market is bifurcated into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

On the basis of treatment, the radiation therapy segment was the major shareholder 2020. In oral cancer, it's usually used after surgery to prevent the cancer returning.

In throat cancer, it's often the first treatment to be given, in combination with chemotherapy medicine (chemoradiotherapy). The treatment is usually given every day over the course of 6 weeks, depending on the size of the cancer and how far it has spread.

Snapshot of North America Oral Cancer Treatment Market  

Increase in demand for surgical therapies for the treatment of oral cancer and rise in investment by governments in research & development to improve treatments boost the global market. North America dominated the global market in 2020 and this trend is projected to continue during the forecast period owing to the rising health care investments in the region and prevalence of oral cancer. The oral cancer treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Rise in tobacco usage, increase in smoking, rapidly expanding health care industry, growing patient population, and high unmet needs are likely to drive the oral cancer treatment market in the region. Further, favorable government policies and rise in disposal income are anticipated to propel the oral cancer treatment market in the region during the forecast period.

The key market players profiled in the report include Bristol-Myers Squibb Company Cipla Inc., Eli-Lilly, F. Hoffmann-La Roche    , Fresenius Kabi AG, Intas Pharmaceuticals Ltd, Merck & Co., Inc., Sanofi, Teva Pharmaceuticals Industries Ltd and Viatris Inc.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the global oral cancer treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

  Oral Cancer Treatment Market Report Highlights

Aspects	Details
By DRUG TYPE	Chemotherapy Immunotherapy Targeted Therapy
By Age Group	30-49 50-69 70<
By End User	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Stores
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	MERCK & CO. INC., VIATRIS INC. (MYLAN N.V), BRISTOL MAYERS SQUIBB COMPANY, ELI-LILLY, CIPLA INC., TEVA PHARMACEUTICALS INDUSTRIES LTD, INTAS PHARMACEUTICALS LTD., F-HOFFMANN-LA-ROCHE, SANOFI S.A, FRESENIUS KABI AG

Analyst Review

Oral cancer includes cancers of the mouth and the back of the throat. Oral cancers develop on the tongue, the tissue lining the mouth and gums, under the tongue, at the base of the tongue, and the area of the throat at the back of the mouth. Furthermore, oral cancer accounts for roughly 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year.

Growing prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also raisingfueling the growth of the market. On the other hand, increasing personal disposable income coupled with rising prevalence of papillomavirus infection is other indirect cause that will create lucrative growth opportunities for the market. However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth.

Author Name(s) : Smita Nerkar | Roshan Deshmukh

Related Tags

• Chemotherapy
• Cancer Diagnostics
• Cancer Drugs

^*Terms and Conditions Apply